Rodman & Renshaw Raises Thoratec PT To $42, Maintains Market Outperform

Rodman & Renshaw raised its Thoratec

price target to $42 in a research report published today. Rodman & Renshaw has a Market Outperform rating on the company. In the report, Rodman & Renshaw stated, "Our field checks now suggest that THOR is on the radar screens of strategics. The newly instituted guidelines from CMS limiting pay for HF readmissions starting Oct 2012, combined with continued issues with competitive pumps is creating a perception of THOR being a solid and accretive acquisition." Shares of Thoratec closed today at $34.52, up 12.04% from Wednesday's market close.